Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Eli Lilly (LLY) reported fourth quarter and full-year earnings for 2024 on Thursday. The results largely beat Wall Street estimates and sent the stock up about 2%. But the company missed on GLP-1 ...

Eli Lilly (LLY) reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street estimates and sending its stock up about 2% in pre-market trading.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...

Lilly didn’t mince words about what sparked that growth, pointing to an impressive 60% sales leap for its type 2 diabetes blockbuster Mounjaro, which brought home $3.5 billion over the last ...